Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial
- 1 November 2015
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 386 (10006), 1825-1834
- https://doi.org/10.1016/s0140-6736(15)00068-9
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ RegistryAmerican Journal of Gastroenterology, 2012
- Practice Patterns in the Use of Anti-Tumor Necrosis Factor Alpha Agents in the Management of Crohn’s Disease: A US National Practice Survey Comparing Experts and Non-ExpertsDigestive Diseases and Sciences, 2010
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Evaluation of the meaningfulness of health‐related quality of life improvements as assessed by the SF‐36 and the EQ‐5D VAS in patients with active Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2009
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990
- Clinical, biological, and endoscopic picture of attacks of Crohn's diseaseGastroenterology, 1990
- The Robust Inference for the Cox Proportional Hazards ModelJournal of the American Statistical Association, 1989
- Longitudinal data analysis using generalized linear modelsBiometrika, 1986
- A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITYThe Lancet, 1980